english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2025 > Prescrire Packaging Awards for 2025 > Prescrire Packaging Awards for 2025

The Prescrire Awards for 2025

Prescrire Packaging Awards for 2025

The Prescrire Packaging Awards for 2025

When Prescrire evaluates a drug's harm-benefit balance, its packaging is an important consideration. Every aspect of the packaging is analysed for its impact on quality of care and the safety of patients and the people around them. We examine, in particular:

  • Whether international nonproprietary names (INNs) are clearly legible, and whether different dose strengths of the same drug are easily distinguishable;
  • The clarity of any information presented graphically, such as diagrams showing how to prepare doses, dosing schedules, symbols or pictograms;
  • The devices provided for dose preparation, measurement or administration;
  • The quality, intelligibility and clarity of the information provided in the patient leaflet, especially in the sections on how to use the product, its adverse effects, and the situations in which the drug poses a particular risk, such as pregnancy or renal impairment;
  • The risk of poisoning, e.g. through accidental ingestion by a child.

The 2025 Prescrire Packaging Awards pertain to the packaging of drugs evaluated in our French edition in 2025.

In 2025, 4 products earned an award for their particularly well-designed packaging:

Le Palmarès des Médicaments
  • Fabhalta° hard capsules (iptacopan) - Novartis
  • Winrevair° powder and solvent for solution for injection (sotatercept) - MSD
  • Flucortac° tablets (fludrocortisone) - HAC Pharma
  • Fludrocortisone Acetlab° tablets (fludrocortisone) - Mitem Pharma 

20 products authorised in the European Union or France in poor­-quality packaging received a "Red Card" for various reasons:

  • Dry oral forms packaged in multidose bottles;
  • Products authorised for paediatric use with an unsuitable dosing device;
  • Risk of wrong-dose errors due to poor labelling of an injectable cytotoxic drug;
  • Packaging that fails to protect users from accidental exposure;
  • Impractical packaging for an injectable drug for use in an emergency setting;
  • Insufficient information about the risks during pregnancy.
     


Download the full article:
Télécharger
 FREE  "The Prescrire Awards for 2025" Prescrire Int 2026; 35 (281): 134-138. FREE.

 

Back to "The Prescrire Awards for 2025"

©Prescrire May 2026      

Filet

Enjoy full access to Prescrire International, and support independent medical information